AIMS AND OBJECTIVES

●       The aim of the present study is to investigate the efficacy of pretreatment with 0.15mg/Kg   cisatracurium in the prevention of propol- associated pain injected 30s before propofol injection with venous occlusion a the forearm. The efficacy of cisatracurium will compared with that of 2% preservative free lidocaine

  MATERIAL AND METHODS

•           This open label prospective, randomized controlled study will be done at PIMS, Jalandhar after approval from institutional ethics committee on 80 patients(40 patients for each group) scheduled to undergo elective non cardiac surgery under general anesthesia of ASA physical status I and II aged 18-65 years.

•       Exclusion Criteria: Patient refusal, Allergy to propofol or egg, limited neck mobility; history of difficult intubation; history of cardiovascular, respiratory, neurological, neuromuscular or psychiatric disease.

•      Patients will be randomly divided into two groups according to computer generated randomization.

•      Group-I:- Pretreatment with 2% Lignocaine 0.5mg/Kg (Preservative free)

•      Group-II: - Pretreatment with 0.15mg/Kg cisatracurium.

•       Patient will be taken to the operative room and ECG, SPO_2, NIBP will be recorded.

•      A 20-G cannula will be inserted into the largest visible vein on the radial side, attached to a three-way tap and flushed with Ringer’s lactate solution.

•      A venous occlusion tourniquet will be applied just above the elbow and pretreatment drug will be administered in open label manner. The tourniquet will be released after 30s. Then 0.5mg/kg propofol will be delivered via the intravenous cannula. In order to evaluate pain and determine the possibility of muscle paralysis, patients will be asked “does it hurt?” by the anesthetist at 10s after the initial propofol dose, and at 20s intervals thereafter until unresponsive. Any spontaneous movement of the wrist, elbow or shoulder will be noted. Pain scores will be evaluated by an anesthetist who will be blinded to group assignment and expressed using a four-point scale:

STATISTICAL ANALYSIS

•      Continuous variables will be expressed as mean ±SD or median (range). Categorical variables were described as n (%).

•      Demographic data will be analyzed with one way analysis of variance and Scheffe’s post hoc test, or X²-test.

•       Between- group variation in the incidence of pain will be analyzed using X²-test. Statistical significant will be defined as P<0.05. Statistical analyses will performed with SPSS.